ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...
Data highlight ILUVIEN’s advantages as the only therapy that consistently treats diabetic macular edema (DME) for up to 3 years ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.
Please provide your email address to receive an email when new articles are posted on . The NEW DAY study did not meet its primary endpoint but showed good outcomes in secondary endpoints. A post hoc ...
Alimera Sciences Limited, the European subsidiary of Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of ...
To report the 12-months visual and anatomical outcomes of chronic diabetic macular oedema (DMO) treated with ILUVIEN in a real-world clinical practice in a single tertiary referral centre.
ATLANTA, Sept. 29, 2014 -- Alimera Sciences, Inc. (ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE)-- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving ...
ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned ...
Marbury Creative Group and Alimera Sciences are aiming to get diabetic macular edema (DME) treatment Iluvien on patients’ radars with the See Less to See More campaign. The nine-month effort, which ...
Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ...
Significantly fewer patients in the fluocinolone acetonide intravitreal implant group experienced recurrence of uveitis at 6 months compared with the sham group. The Food and Drug Administration (FDA) ...
We report the clinical efficacy and safety of intravitreal Iluvien implant in vitrectomised eyes of chronic diabetic macular oedema (DMO), irrespective of the timing of vitrectomy procedure. Case 1 A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results